多发性硬化症的治疗进展。
Update on treatment in multiple sclerosis.
机构信息
Department of Biomedicine, University Hospital Basel, University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland.
Department of Biomedicine, University Hospital Basel, University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland; Department of Neurology, University Hospital Basel, University of Basel, Petersgraben 4, 4031 Basel, Switzerland.
出版信息
Presse Med. 2021 Jun;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Epub 2021 May 24.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In recent years, many disease-modifying therapies (DMT) have been approved for MS treatment. For this reason, a profound knowledge of the characteristics and indications of the available compounds is required to tailor the therapeutic strategy to the individual patient characteristics. This should include the mechanism of action and pharmacokinetic of the drug, the safety and efficacy profile provided by clinical trials, as well as the understanding of possible side effects. Moreover, the evolving knowledge of the disease is paving the way to new and innovative therapeutic approaches, as well as the development of new biomarkers to monitor the therapeutic response and to guide the clinician's therapeutic choices. In this review we provide a comprehensive overview on currently approved therapies in MS and the emerging evidence-based strategies to adopt for initiating, monitoring, and eventually adapting a therapeutic regimen with DMT.
多发性硬化症（MS）是一种中枢神经系统的慢性炎症性疾病。近年来，许多疾病修正治疗（DMT）药物已被批准用于 MS 的治疗。因此，需要深入了解现有化合物的特点和适应证，以便根据患者的个体特征制定治疗策略。这应包括药物的作用机制和药代动力学、临床试验提供的安全性和疗效概况，以及对可能出现的副作用的理解。此外，对疾病的不断深入了解正在为新的和创新的治疗方法以及新的生物标志物的开发铺平道路，以监测治疗反应并指导临床医生的治疗选择。在这篇综述中，我们全面概述了目前批准用于 MS 的治疗方法，以及为启动、监测和最终调整 DMT 治疗方案而采用的新的基于证据的策略。
Zotero 插件